Description

Alluvi Retatrutide

Alluvi retatrutide offers a wellness‑oriented platform combining precision‑dosed retatrutide injections with structured tracking and nutritional support to optimize weight loss. Their ready‑to‑use pens eliminate mixing errors and ensure consistent dosing. Clinical data from their system show participants achieving up to 22.5 % body‑weight reduction, averaging 18.3 kg lost over 48 weeks, partly driven by an average 600‑calorie daily intake reduction and reported boosts in energy levels (~28 %) . The integrated tracking tool enables users to log nutrition and receive weekly progress summaries, reinforcing adherence. While promising, Alluvi’s figures align with phase 2 trial outcomes for retatrutide (up to 24.2 % weight loss at 48 weeks with the highest dose) . Retatrutide remains investigational; long‑term safety, broader efficacy, and official approval are pending further trial results.